Sobi® (STO: SOBI) will be presenting a wide range of clinical study updates at the annual International Society on Thrombosis and Haemostasis (ISTH) Congress in Washington (21-25 June). With ten (10) presentations, Sobi’s clinical teams will showcase new data for avatrombopag to treat children with ITP, surgery outcomes using efanesoctocog alfa, and abstracts on specific long-term haemophilia studies.
“Attending ISTH is an important part of our commitment to collaboration and knowledge sharing so we can further advance treatments for those living with haemophilia, immune thrombocytopenia, and other rare blood conditions”, said Lydia Abad-Franch, MD, Head of R&D and Medical Affairs, and Chief Medical Officer at Sobi.
“We are proud to be showcasing abstracts as part of the ISTH programme, including Doptelet abstracts that present new data related to children living with ITP, Altuvoct outcomes for perioperative management, and joint health outcomes from a long-term extension study, as well as final outcomes from the B-MORE study. Many people living with rare conditions have unmet needs, and we are proud to present additional data advancing treatments for these rare conditions.”
Data to be presented at ISTH 2025
|
ALTUVOCT® (efanesoctocog alfa) |
|
|
OC 64.4: Major Surgical Outcomes with Efanesoctocog Alfa: 4 Years’ Experience in the XTEND Clinical Program
Presenting author: Liane Khoo |
Oral presentation Session date: Tuesday 24 June Session time: 14:45 - 16:00 EDT Location: 151 A&B, Walter E. Washington CC Convention Center |
|
OC 20.5: Treatment of Bleeding Episodes with Efanesoctocog Alfa in Children: XTEND-ed Second Interim Analysis
Presenting author: Lynn Malec |
Oral presentation Session date: Sunday 22 June Session time: 14:45 - 16:00 EDT Location: Ballroom A-C, Walter E. Washington CC Convention Center |
|
PB0847: Minor Surgeries Outcomes with Efanesoctocog Alfa: 4 Years’ Experience in the XTEND Clinical Program
Presenting author: Pratima Chowdary |
Poster presentation Session date: Monday 23 June Session time: 13:45 – 14:45 EDT Location: Exhibition Hall |
|
PB1425: Joint Health Outcomes with Efanesoctocog Alfa in Adults/Adolescents from XTEND-1 Continuing XTEND-ed
Presenting author: Christoph Königs |
Poster presentation Session date: Tuesday 24 June Session time: 13:45 – 14:45 EDT Location: Exhibition Hall |
|
General Haemophilia |
|
|
PB0778: Addressing unmet medical needs and health inequities in haemophilia A: expert consensus statements
Presenting author: Cédric Hermans |
Poster presentation Session date: Monday 23 June Session time: 13:45 – 14:45 EDT Location: Exhibition Hall |
|
PB0816: Extravascular distribution of factor IX: evidence and relevance for haemophilia B replacement therapy
Presenting author: Cédric Hermans |
Poster presentation Session date: Monday 23 June Session time: 13:45 – 14:45 EDT Location: Exhibition Hall |
|
PB1439: Monitoring Joint Health in Haemophilia Patients in Spain: Updated Analysis of the JOIN-US Project
Presenting author: María Teresa Álvarez Román |
Poster presentation Session date: Tuesday 24 June Session time: 13:45 – 14:45 EDT Location: Exhibition Hall |
|
ALPROLIX® (rFIXFc) |
|
|
PB0868: Real-World Effectiveness and Usage of Recombinant Factor IX Fc: Final Data from the B-MORE Study
Presenting author: Heidi Glosli |
Poster presentation Session date: Monday 23 June Session time: 13:45 – 14:45 EDT Location: Exhibition Hall |
|
Doptelet® (avatrombopag) |
|
|
PB0348: Consistent Response to Avatrombopag for the Treatment of Children with ITP Across Various Baseline Characteristics
Presenting author: Rachael F. Grace |
Poster presentation Session date: Sunday 22 June Session time: 13:45 - 14:45 EDT Location: Exhibition hall |
|
PB0364: Evaluation of Efficacy and Safety of Avatrombopag in Children with ITP Based on Disease Duration
Presenting author: Rachael F. Grace |
Poster presentation Session date: Sunday 22 June Session time: 13:45 - 14:45 EDT Location: Exhibition hall |
|
OC 65.3: Real-World Outcomes of Avatrombopag Treatment in Primary ITP Stratified by Prior TPO-RA Exposure
Presenting author: Srikanth Nagalla |
Oral presentation Session date: Tuesday 24 June 2025 Session time: 14:45 – 16:00 EDT (Presentation time currently in programme: 15:15 – 15:30 EDT) |
All abstracts are accessible through the official ISTH website. However, any late-breaking abstracts will only be made available later.
ALTUVOCT® (efanesoctocog alfa) is indicated for the treatment and prophylaxis of bleeding in patients with haemophilia A. ALTUVOCT can be used for all age groups and any disease severity.
Elocta®/Eloctate® (efmoroctocog alfa) is a treatment and prophylaxis of bleeding in patients with haemophilia A. Elocta/Eloctate can be used for all age groups.
Alprolix® (eftrenonacog alfa) is a treatment and prophylaxis of bleeding in patients with haemophilia B. Alprolix can be used for all age groups.
About Doptelet® (avatrombopag)
Doptelet® (avatrombopag) is indicated for the treatment of primary chronic immune thrombocytopenia (ITP) in adult patients who are refractory to other treatments, and a treatment of severe thrombocytopenia in adult patients with chronic liver disease (CLD) who are scheduled to undergo an invasive procedure.
About Sobi
Sobi is a global biopharma company unlocking the potential of breakthrough innovations, transforming everyday life for people living with rare diseases. Sobi has approximately 1,900 employees across Europe, North America, the Middle East, Asia and Australia. In 2024, revenue amounted to SEK 26 billion. Sobi’s share (STO:SOBI) is listed on Nasdaq Stockholm. More about Sobi at sobi.com and LinkedIn.
About Sanofi
Sanofi is an R&D driven, AI-powered biopharma company committed to improving people’s lives and delivering compelling growth. Sanofi apply deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Sanofi’s team is guided by one purpose: to chase the miracles of science to improve people’s lives; this inspires Sanofi to drive progress and deliver positive impact for Sanofi’s people and the communities Sanofi serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time.
Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY
About the Sanofi and Sobi collaboration
Sobi and Sanofi collaborate on the development and commercialisation of Alprolix and Elocta/Eloctate. The companies also collaborate on the development and commercialisation of efanesoctocog alfa, or ALTUVIIIO® in the US, Japan, and Taiwan, and Altuvoct in Europe. Sobi has final development and commercialisation rights in the Sobi territory (essentially Europe, North Africa, Russia, and most Middle Eastern markets). Sanofi has final development and commercialisation rights in North America and all other regions in the world excluding the Sobi territory.
Contacts
For details on how to contact the Sobi Investor Relations Team, please click here. For Sobi Media contacts, click here.
We are a global biopharma company unlocking the potential of breakthrough innovations, transforming everyday life for people living with rare diseases.
Our therapies are concentrated within the areas of Haematology, Immunology and Specialty Care.
We contribute to societies by improving access to treatment of rare diseases.
Every day, we work actively to find better ways to understand and meet patient needs.
Find out more about our business and financial performance.
Here we present our most recent press releases, news articles, and images.